eng Oriental Scientific Publishing Company Biomedical and Pharmacology Journal 0974-6242 2025-09-30 18 3 2228 2238 10.13005/bpj/3249 67863 article Ni Nyoman Budiani 1 Lely Cintari 1 Ni Komang Wiardani 1 Listina Ade Widya Ningtyas 1 Gusti Ayu Tirtawati 1 Midwifery Department, Health Polytechnic Denpasar, Bali, Indonesia Diabetes mellitus is a rising global health concern. This study aimed to determine the effect of Cersenlau sugar on fasting blood glucose, 2-hour postprandial blood glucose, and HbA1c levels in type 2 diabetes mellitus (DM) rats and healthy adults. The research involved two phases: the first phase utilized a true experimental pretest-posttest control group design with 27 alloxan-induced Wistar rats, while the second phase employed a quasi-experimental nonequivalent control group design with 44 healthy adults. The intervention lasted two weeks, during which blood glucose and HbA1c levels were measured before and after. Statistical analysis included ANOVA and MANOVA. Results showed that in the first phase, fasting glucose, postprandial glucose, and HbA1c significantly decreased in the intervention group. In the second phase, Cersenlau sugar reduced body weight but did not significantly affect glucose or HbA1c levels, whereas commercial sugar increased 2-hour postprandial glucose levels. The findings suggest that Cersenlau sugar has potential as a therapeutic agent for type 2 diabetes mellitus and could serve as a health-promoting sweetener for healthy individuals. However, this study is limited by the small sample size and gender imbalance in Phase II, warranting cautious interpretation and the need for a larger, balanced study. This preliminary finding requires confirmation in longer-term studies with diabetic or prediabetic patients. https://biomedpharmajournal.org/vol18no3/potential-of-cersenlau-sugar-as-a-therapeutic-sugar-agent-evidence-from-rat-models-and-healthy-adults/ Antioxidants Blood Glucose Control Cersenlau Sugar Therapeutic Sweetener Type 2 Diabetes Mellitus